AstraZeneca Announces Potential Breakthrough in Advanced Biliary Tract CancerAstraZeneca, Biliary Tract Cancer, Blockbusters, Chemotherapy, Cholangiocarcinoma, Clinical Trials, Gall Bladder, Overall Survival (OS), R&D, TherapeuticsAstraZeneca shared positive results from the company’s TOPAZ-1 Phase III trial on Imfinzi (durvalumab) in increasing the chances for survival in advanced biliary tract cancer patients when combined with standard-of-care chemotherapy regimens. Read more October 25, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/10/AstraZeneca-Announces-Potential-Breakthrough-in-Advanced-Biliary-Tract-Cancer-BioSpace-10-25-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-10-25 13:58:292021-10-25 14:14:56AstraZeneca Announces Potential Breakthrough in Advanced Biliary Tract Cancer